Preparing Your Lab for an FDA Inspection

Although most clinical laboratories interact primarily with Clinical Laboratory Improvement Amendments (CLIA) surveyors and accrediting organizations, FDA inspections remain an important consideration for laboratories that manufacture or commercialize in vitro diagnostics, support regulated clinical investigations or otherwise fall within FDA’s jurisdiction. FDA inspections of clinical laboratories rarely begin by evaluating whether a laboratory can perform a particular test. Instead, inspectors often focus on determining how decisions were made, who made them, what documentation governed the work and whether the record supports those answers. Many labs prepare for FDA inspections by refreshing standard operating procedures (SOPs) and organizing their quality records. Those efforts matter. However, even an organized quality manual system does not help if personnel cannot answer inspectors’ questions.

Five areas deserve attention before an FDA inspector asks about them.

1. Document control is often the first thing inspectors test. Inspectors often begin by comparing the controlled version of a document with what is used at the bench. Version mismatches, unsigned SOPs and outdated forms are among the most frequently cited observations. Individual issues can often be corrected during an inspection, but repeated inconsistencies suggest gaps between written procedures and day-to-day practice.
   
2. Complaint files get more scrutiny than most labs expect. If a laboratory has received complaints, whether from clinicians, patients or internal quality channels, FDA will want to see how each complaint was received, investigated and resolved. Laboratories that do not maintain a formal complaint handling process or that handle complaints informally without documentation tend to generate findings in this area. The expectation is a written procedure, consistent execution and traceable records.
   
3. Corrective and preventive action (CAPA) systems must have substance. Inspectors assess whether CAPAs address root causes rather than symptoms, whether effectiveness checks are performed and documented, and whether the CAPA process drives changes in operations. A CAPA log full of entries that conclude with “re-trained staff” without further analysis is a common red flag — particularly if staff cannot recall what training occurred.
   
4. Personnel qualification and competency records must hold up under specific questioning. FDA inspectors may ask to see training records, competency assessments and qualification documentation for specific personnel performing specific tasks. General training logs that do not connect individual employees to the procedures they perform are insufficient. The expectation is that labs can demonstrate, for any given test or process, that the person performing it was qualified and assessed as competent to do so.
   
5. Validation and change-control records should tell a complete story. Laboratories frequently modify assays, qualify new reagent suppliers, revise procedures, replace instruments or implement software changes. Inspectors may ask why a change was made, who approved it, whether additional validation was performed and when the revised procedure became effective. Change-control records should allow the laboratory to reconstruct that history without relying on institutional memory.

What This Looks Like in Practice

A lab may believe it is ready for an FDA inspection because its SOPs are current and the quality manual is polished. Then the inspector asks who approved a particular change, which version of an SOP governed the work on a specific date, or where the raw validation data can be found for a specific validation run. The laboratory can clearly perform the work, but if it cannot reconstruct the record quickly enough to answer straightforward questions, the inspector’s questions are likely to become more challenging.

The Readout

Missing signatures and outdated policies matter. More significant findings usually emerge when the laboratory cannot explain how its quality system functions. These findings can trigger remediation projects that delay product timelines, complicate financing discussions and create additional diligence requests during transactions. Sponsors and investors treat inspection outcomes as credibility signals, and a weak inspection story can slow fundraising or inject new representations and warranties into a deal.

Laboratories generally have smoother FDA inspections when they can explain their work as clearly as they perform it. Documents match practice. Records are retrievable. Staff can explain what they did, when they did it and why.

The Lab Protocol is for informational and educational purposes only and does not constitute legal, regulatory or compliance advice. Readers should consult qualified counsel regarding their specific circumstances.